NTRB - NASDAQ
Nutriband Inc.
$4.15
-0.72%Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
At a Glance
Live SnapshotNutriband Inc. Management Team
Mr. Gerald Goodman
Chief Financial Officer & Chief Accounting Officer
Compensation
$115,000
Dr. Alan Smith Ph.D.
Chief Operating Officer & President of 4P Therapeutics
Compensation
$159,000
Dr. Jeffrey Patrick Pharm.D.
Chief Scientific Officer
Mr. Gareth Sheridan
Founder, Chief Executive Officer & Director
Compensation
$155,000
Mr. Serguei Melnik
Founder, President, Company Secretary & Executive Chairman of the Board
Compensation
$155,000
Mr. Tyler Overk
Head of Active Intelligence
Mr. Michael Myer
President of Pocono Pharmaceutical
Compensation
$40,600
Nutriband Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for NTRB.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
NTRB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | December 19, 2025 | January 24, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | December 16, 2024 | January 23, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | December 15, 2023 | January 21, 2024 | 2024 | |
DEF 14A DEF 14A 2022 N/A | October 31, 2022 | December 09, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | December 09, 2021 | January 21, 2022 | 2022 | |
DEF 14A DEF 14A 2020 N/A | January 09, 2020 | January 21, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.